LATAM Airlines Group reported impressive traffic figures for July, wherein load factor (% of seats filled by passengers) improved as traffic growth was more than capacity expansion in the month.
Consolidated traffic (measured in revenue passenger kilometers or RPKs) came in at 11.13 billion, up 3.9% from the year-ago figure. On a year-over-year basis, consolidated capacity (or available seat miles/ASMs) rose 3.4% to 13.18 billion.
Moreover, consolidated load factor improved to 84.5% from 84% a year ago. Passenger count climbed 7.8% to 6.7 million.
In the first seven months of 2019, LATAM Airlines, which competes with the likes of GOL Linhas , Azul (AZUL - Free Report) and Copa Holdings (CPA - Free Report) in the Latin American aviation space, generated RPKs of 72.13 billion (up 5.8% year over year) and ASMs of 86 billion (up 5.4% year over year). Load factor registered an increase of 0.3 percentage points year over year to 83.9%. Passenger count at LATAM Airlines increased 7.2% on a year-to-date basis.
Notably, LATAM Airlines is being aided by an increase in passenger revenues lately. In the second quarter of 2019, passenger revenues, which accounted for 85.2% of the top line, improved 3.2% year over year. The metric was driven by a 4.8% capacity expansion in the quarter.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
LATAM Airlines Group reported impressive traffic figures for July, wherein load factor (% of seats filled by passengers) improved as traffic growth was more than capacity expansion in the month.
Consolidated traffic (measured in revenue passenger kilometers or RPKs) came in at 11.13 billion, up 3.9% from the year-ago figure. On a year-over-year basis, consolidated capacity (or available seat miles/ASMs) rose 3.4% to 13.18 billion.
Moreover, consolidated load factor improved to 84.5% from 84% a year ago. Passenger count climbed 7.8% to 6.7 million.
In the first seven months of 2019, LATAM Airlines, which competes with the likes of GOL Linhas , Azul (AZUL - Free Report) and Copa Holdings (CPA - Free Report) in the Latin American aviation space, generated RPKs of 72.13 billion (up 5.8% year over year) and ASMs of 86 billion (up 5.4% year over year). Load factor registered an increase of 0.3 percentage points year over year to 83.9%. Passenger count at LATAM Airlines increased 7.2% on a year-to-date basis.
Notably, LATAM Airlines is being aided by an increase in passenger revenues lately. In the second quarter of 2019, passenger revenues, which accounted for 85.2% of the top line, improved 3.2% year over year. The metric was driven by a 4.8% capacity expansion in the quarter.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CPA - FREE
Get the latest research report on AZUL - FREE